Retinopathy - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Retinopathy - Pipeline Review, H1 2016

Retinopathy - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Retinopathy - Pipeline Review, H1 2016
Published Jun 08, 2016
79 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Retinopathy - Pipeline Review, H1 2016, provides an overview of the Retinopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinopathy and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Retinopathy
- The report reviews pipeline therapeutics for Retinopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Retinopathy therapeutics and enlists all their major and minor projects
- The report assesses Retinopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Retinopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Retinopathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Retinopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-lic

  
Source:
Document ID
GMDHC8185IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Retinopathy Overview71
Therapeutics Development82
  Pipeline Products for Retinopathy Overview81
  Pipeline Products for Retinopathy Comparative Analysis91
Retinopathy Therapeutics under Development by Companies101
Retinopathy Therapeutics under Investigation by Universities/Institutes111
Retinopathy Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Retinopathy Products under Development by Companies151
Retinopathy Products under Investigation by Universities/Institutes161
Retinopathy Companies Involved in Therapeutics Development178
  Acucela Inc.171
  Biomar Microbial Technologies181
  Biophytis SAS191
  Edison Pharmaceuticals, Inc.201
  F. Hoffmann-La Roche Ltd.211
  Insmed Incorporated221
  Navigen Pharmaceuticals, Inc.231
  RedHill Biopharma Ltd.241
Retinopathy Therapeutics Assessment259
  Assessment by Monotherapy Products251
  Assessment by Target262
  Assessment by Mechanism of Action282
  Assessment by Route of Administration302
  Assessment by Molecule Type322
Drug Profiles3428
  ABC-294640 - Drug Profile341
    Product Description341
    Mechanism of Action341
    R&D Progress343
  AP-202 - Drug Profile371
    Product Description371
    Mechanism of Action371
    R&D Progress371
  BIO-201 - Drug Profile381
    Product Description381
    Mechanism of Action381
    R&D Progress381
  BIO-203 - Drug Profile391
    Product Description391
    Mechanism of Action391
    R&D Progress391
  emixustat hydrochloride - Drug Profile401
    Product Description401
    Mechanism of Action401
    R&D Progress402
  IB-09A0133 - Drug Profile421
    Product Description421
    Mechanism of Action421
    R&D Progress421
  IB-12A157 - Drug Profile431
    Product Description431
    Mechanism of Action431
    R&D Progress431
  mecasermin rinfabate (recombinant) - Drug Profile441
    Product Description441
    Mechanism of Action441
    R&D Progress443
  NAV-2729 - Drug Profile471
    Product Description471
    Mechanism of Action471
    R&D Progress473
  R-200 - Drug Profile501
    Product Description501
    Mechanism of Action501
    R&D Progress501
  ranibizumab - Drug Profile511
    Product Description511
    Mechanism of Action511
    R&D Progress514
  Recombinant Protein for Cancer and Diabetic Retinopathy - Drug Profile551
    Product Description551
    Mechanism of Action551
    R&D Progress551
  Recombinant Protein for Oncology and Ophthalmology - Drug Profile561
    Product Description561
    Mechanism of Action561
    R&D Progress561
  Small Molecule for Retinopathy of Prematurity - Drug Profile571
    Product Description571
    Mechanism of Action571
    R&D Progress571
  Small Molecules to Inhibit Eya Tyrosine Phosphatase for Solid Tumors and Retinopathy - Drug Profile581
    Product Description581
    Mechanism of Action581
    R&D Progress581
  vatiquinone - Drug Profile591
    Product Description591
    Mechanism of Action591
    R&D Progress593
Retinopathy Recent Pipeline Updates6213
Retinopathy - Dormant Projects751
Retinopathy Discontinued Products761
Retinopathy Product Development Milestones771
  Featured News &Press Releases771
    Jan 21, 2009: Insmed And Premacure Announce European Orphan Designation For IPLEX In Retinopathy Of Prematurity In Infants771
    Apr 29, 2008: Acucela Presents Preclinical Data From Retinopathy Study Demonstrating Improvement In Retinal Abnormalities771
Appendix782
  Methodology781
  Coverage781
  Secondary Research781
  Primary Research781
  Expert Panel Validation781
  Contact Us781
  Disclaimer791

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Retinopathy - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Retinopathy-Pipeline-Review-H1-2016-2088-15917>
  
APA:
Global Markets Direct - Market Research. (2016). Retinopathy - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Retinopathy-Pipeline-Review-H1-2016-2088-15917>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.